Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Abbott |
---|---|
Information provided by: | Abbott |
ClinicalTrials.gov Identifier: | NCT00077779 |
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
Condition | Intervention | Phase |
---|---|---|
Crohn's Disease |
Drug: Adalimumab |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion:
Exclusion:
Study Director: | Paul F Pollack, M.D. | Abbott |
Study ID Numbers: | M02-404 |
Study First Received: | February 12, 2004 |
Last Updated: | September 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00077779 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Anti-Inflammatory Agents Crohn's Disease Ileitis Gastrointestinal Diseases Enteritis Inflammatory Bowel Diseases Intestinal Diseases Adalimumab |
Ileal Diseases Antibodies, Monoclonal Antibodies Digestive System Diseases Crohn Disease Antirheumatic Agents Gastroenteritis Immunoglobulins |
Anti-Inflammatory Agents Ileitis Gastrointestinal Diseases Enteritis Inflammatory Bowel Diseases Intestinal Diseases Adalimumab |
Ileal Diseases Pharmacologic Actions Digestive System Diseases Therapeutic Uses Crohn Disease Gastroenteritis Antirheumatic Agents |